Luepke KH, Mohr JF III. The antibiotic pipeline: reviving research and development and speeding drugs to market. Expert Rev Anti Infect Ther. 2017 May;15(5):425-433. Available from: https://doi.org/10.1080/14787210.2017.1308251
When the above article was first published online, the Introduction contained an error. Please see below for the original text and the corrected version.
Original text:
A recent report by Reuters in collaboration with the CDC’s National Center for Health Statistics’ Division of Vital Statistics actually estimated >180,000 annual deaths due to drug-resistant infections overall compared to the original CDC estimate[2]. This new prediction may also be an underestimate due to lack of documentation on death certificates and lack of a unified surveillance system for drug-resistant infections.
Corrected version:
A recent report by Reuters in collaboration with the CDC’s National Center for Health Statistics’ Division of Vital Statistics estimated >200,000 deaths due to drug-resistant infections from 2003-2014. However, both numbers are underestimates due to the lack of a unified surveillance system for drug-resistant infections as well as a lack of documentation on death certificates.
The authors apologise for this error.